Do analysts recommend MIRA or CVKD?

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 570.10%. Given Cadrenal Therapeutics' higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, MIRA or CVKD?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is MIRA or CVKD more profitable?

MIRA Pharmaceuticals' return on equity of -140.82% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Cadrenal Therapeutics N/A -411.03% -275.61%

Does the media refer more to MIRA or CVKD?

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.37 beat Cadrenal Therapeutics' score of 0.85 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ACTU or CVKD?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is ACTU or CVKD more profitable?

Cadrenal Therapeutics' return on equity of -411.03% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Cadrenal Therapeutics N/A -411.03% -275.61%

Which has preferable earnings and valuation, PSTV or CVKD?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Does the media refer more to PSTV or CVKD?

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Plus Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.85 beat Plus Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CVKD or TXMD?

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 570.10%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Cadrenal Therapeutics (CVKD) Competitors

$1.94 -0.01 (-0.51%)

As of 04:00 PM Eastern

Compare

CVKD vs. MIRA, ACTU, PSTV, AYTU, and TXMD

Should you buy Cadrenal Therapeutics stock or one of its competitors? Cadrenal Therapeutics's main competitors and comparable companies include MIRA Pharmaceuticals (MIRA), Actuate Therapeutics (ACTU), Plus Therapeutics (PSTV), Aytu BioPharma (AYTU), and TherapeuticsMD (TXMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cadrenal Therapeutics compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 570.10%. Given Cadrenal Therapeutics' higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MIRA Pharmaceuticals' return on equity of -140.82% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 1.37 beat Cadrenal Therapeutics' score of 0.85 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MIRA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadrenal Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MIRA Pharmaceuticals has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market.

Summary

MIRA Pharmaceuticals beats Cadrenal Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Cadrenal Therapeutics' return on equity of -411.03% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Actuate Therapeutics presently has a consensus target price of $13.67, suggesting a potential upside of 1,239.87%. Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 570.10%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Actuate Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for Actuate Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.85 beat Actuate Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
Cadrenal Therapeutics	Positive

Summary

Cadrenal Therapeutics beats Actuate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Cadrenal Therapeutics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Plus Therapeutics currently has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Cadrenal Therapeutics has a consensus price target of $13.00, indicating a potential upside of 570.10%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Plus Therapeutics is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Plus Therapeutics. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Plus Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.85 beat Plus Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadrenal Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Plus Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Summary

Cadrenal Therapeutics beats Plus Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Aytu BioPharma?

Cadrenal Therapeutics (NASDAQ:CVKD) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

Cadrenal Therapeutics has a beta of 1.84, meaning that its stock price is 84% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market.

Cadrenal Therapeutics presently has a consensus price target of $13.00, indicating a potential upside of 570.10%. Aytu BioPharma has a consensus price target of $10.75, indicating a potential upside of 351.68%. Given Cadrenal Therapeutics' higher possible upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cadrenal Therapeutics has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Aytu BioPharma	$66.38M	0.38	-$13.56M	-$4.58	N/A

Cadrenal Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 14.6% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for Aytu BioPharma. Cadrenal Therapeutics' average media sentiment score of 0.85 beat Aytu BioPharma's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Aytu BioPharma	Neutral

Summary

Cadrenal Therapeutics beats Aytu BioPharma on 8 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to TherapeuticsMD?

Cadrenal Therapeutics (NASDAQ:CVKD) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 14.6% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 570.10%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50

TherapeuticsMD has a net margin of 5.34% compared to Cadrenal Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
TherapeuticsMD	5.34%	0.32%	0.23%

In the previous week, Cadrenal Therapeutics had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 0 mentions for TherapeuticsMD. Cadrenal Therapeutics' average media sentiment score of 0.85 beat TherapeuticsMD's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
TherapeuticsMD	Neutral

Cadrenal Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

TherapeuticsMD beats Cadrenal Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.66M	$11.84B	$7.02B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-0.34	649.40	210.34	20.96
Price / Sales	N/A	740.84	588.78	86.31
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	1.66	10.33	11.27	6.42
Net Income	-$13.24M	$2.77B	$3.45B	$347.03M
7 Day Performance	-1.02%	2.04%	3.56%	2.48%
1 Month Performance	-32.87%	-1.57%	-0.58%	-1.04%
1 Year Performance	-82.60%	191.33%	77.52%	23.22%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	3.3062 of 5 stars	$1.94 -0.5%	$13.00 +570.1%	-82.5%	$6.66M	N/A	N/A	4
MIRA MIRA Pharmaceuticals	0.7427 of 5 stars	$0.68 +10.0%	N/A	-46.4%	$25.80M	N/A	N/A	2	Positive News Gap Up High Trading Volume
ACTU Actuate Therapeutics	1.8695 of 5 stars	$1.12 +5.7%	$13.67 +1,120.2%	-86.2%	$25.36M	N/A	N/A	10	Gap Up
PSTV Plus Therapeutics	1.7929 of 5 stars	$3.52 -9.0%	$56.40 +1,502.3%	-80.7%	$24.22M	$5.21M	N/A	20	Upcoming Earnings Gap Down
AYTU Aytu BioPharma	1.8023 of 5 stars	$2.21 -1.8%	$10.75 +386.4%	-0.4%	$24.15M	$66.38M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. MIRA, ACTU, PSTV, AYTU, and TXMD

How does Cadrenal Therapeutics compare to MIRA Pharmaceuticals?

Summary

How does Cadrenal Therapeutics compare to Actuate Therapeutics?

Summary

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Summary

How does Cadrenal Therapeutics compare to Aytu BioPharma?

Summary

How does Cadrenal Therapeutics compare to TherapeuticsMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. MIRA, ACTU, PSTV, AYTU, and TXMD

How does Cadrenal Therapeutics compare to MIRA Pharmaceuticals?

Do analysts recommend MIRA or CVKD?

Is MIRA or CVKD more profitable?

Do insiders and institutionals have more ownership in MIRA or CVKD?

Which has preferable valuation & earnings, MIRA or CVKD?

Does the media refer more to MIRA or CVKD?

Which has more volatility and risk, MIRA or CVKD?

Summary

How does Cadrenal Therapeutics compare to Actuate Therapeutics?

Do insiders and institutionals believe in ACTU or CVKD?

Which has better valuation and earnings, ACTU or CVKD?

Is ACTU or CVKD more profitable?

Do analysts rate ACTU or CVKD?

Which has more volatility & risk, ACTU or CVKD?

Does the media refer more to ACTU or CVKD?

Summary

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Is PSTV or CVKD more profitable?

Do analysts prefer PSTV or CVKD?

Do insiders and institutionals have more ownership in PSTV or CVKD?

Which has more risk and volatility, PSTV or CVKD?

Does the media refer more to PSTV or CVKD?

Which has preferable earnings and valuation, PSTV or CVKD?

Summary

How does Cadrenal Therapeutics compare to Aytu BioPharma?

Which has more volatility and risk, CVKD or AYTU?

Do analysts recommend CVKD or AYTU?

Which has higher earnings and valuation, CVKD or AYTU?

Is CVKD or AYTU more profitable?

Do institutionals and insiders have more ownership in CVKD or AYTU?

Does the media prefer CVKD or AYTU?

Summary

How does Cadrenal Therapeutics compare to TherapeuticsMD?

Do institutionals and insiders hold more shares of CVKD or TXMD?

Do analysts recommend CVKD or TXMD?

Which has preferable valuation and earnings, CVKD or TXMD?

Is CVKD or TXMD more profitable?

Does the media refer more to CVKD or TXMD?

Which has more volatility and risk, CVKD or TXMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools